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Abstract
Purpose of review The targeted approach adopted for Barrett’s oesophagus (BO) screening
is sub-optimal considering the large proportion of BO cases that are currently missed. We
reviewed the literature highlighting recent technological advancements in efforts to
counteract this challenge. We also provided insights into strategies that can improve
the outcomes from current BO screening practises.
Recent findings The standard method for BO detection, endoscopy, is invasive and
expensive and therefore inappropriate for mass screening. On the other hand, endoscopy
is more cost-effective for screening a high-risk population. A consensus has however not
been reached on who should be screened. Risk prediction algorithms have been tested as
an enrichment pre-screening tool reporting modest AUC’s but require more prospective
evaluation studies. Less invasive endoscopy methods like trans-nasal endoscopy, oesoph-
ageal capsule endsocopy and non-endoscopic cell collection devices like the Cytosponge
coupled with biomarker analysis have shown promise in BO detection with randomised
clinical trial evidence.
Summary A three-tier precision cancer programme whereby risk prediction algorithms and
non-endoscopic minimally invasive cell collection devices are used to triage test a wider
pool of individuals may improve the detection rate of current screening practises with
minimal cost implications.
Published online: 16 March 2021
Introduction
Oesophageal adenocarcinoma (OAC) is a poor progno-
sis cancer [1] that is often preceded by histologically
defined premalignant lesions called Barrett’s oesopha-
gus (BO). This provides excellent opportunities for
screening (identification of the disease) and surveillance
(disease monitoring). Pre-emptive screening and sur-
veillance programmes could have a big impact on out-
comes, survival and comorbidity associated with treat-
ment, since outpatient-based endoscopic therapies for
premalignant lesions can prevent invasive disease. To
date the mainstay for diagnosis and monitoring has
been endoscopic-based technology [2]; however, the
relative expensive and invasive natures of oesophago-
gastro-duodenoscopy (OGD) impede the effective im-
plementation of using this diagnostic modality in a
population-wide screening programme. This has be-
come even more apparent with the pressures on diag-
nostic services during the coronavirus pandemic. These
limitations have thus warranted development of other
less invasive, more affordable screening tools for mass
screening as well as for surveillance and diagnostic
triage.
Challenges associated with current screening guidelines
The precursor lesion for OAC is non-dysplastic BO (NDBO) which can subse-
quently progress to low-grade dysplasia (LGD), high-grade dysplasia (HGD)
and eventually to OAC [3]. The annual risk of progression to OAC steadily
increases from 0.1 to 0.5% in NDBO to 6% or more in HGD [4–7]. In some
cases, progression can be rapid without opportunity to diagnose intermediate
dysplastic steps. However, since population-based studies show that BO diag-
nosis prior to OAC detection decreases diseasemortality [8], and since there has
been such an improvement in outpatient, endoscopic therapies for early dis-
ease, there is a strong rationale for programmes to improve detection of BO.
A recent systematic review and meta-analysis of papers from the past 10
years reported that 11.8% of OAC cases had a known diagnosis of BO [9••],
even taking into account increasing endoscopy volumes [6, 10–12]. There are
several likely explanations behind the substantial numbers of missed screening
opportunities for patients with undiagnosed BO. The societal screening guide-
lines are recommendations, but national public health agencies have not
enforced OGD-based mass screening owing to the poor cost benefits and
potential morbidity associated with using endoscopy as a screening tool for a
relatively uncommon disease. This is especially the case when compared to the
higher prevalence of other cancer types like breast and colon. Although there is
consensus on the role of BO as a risk factor for OAC and the need for some form
of screening, there are different views on “who”, “when” and “how” to screen.
Furthermore, these guidelines are not always supported by high-quality evi-
dence and are rather based on expert opinions [13]. Moreover, the cost efficacy
and improvedmortality rate of this targeted screening approach has never been
evaluated.
In terms of who to screen, guidelines from all societies thus restrict screening
to more targeted high-risk populations [2, 14–18]. Both genetic and non-
genetic risk factors have been identified for OAC.However, polygenic risk scores
are not yet being applied clinically and family history is used as a proxymeasure
of inherited genetic risk [19]. Regarding non-genetic factors, chronic and fre-
quent gastroesophageal reflux disease (GORD) is the most significant and well-
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studied. A landmark population-based case-control study demonstrated that
patients with GORD had a significantly greater risk of developing OAC as
compared with asymptomatic individuals with an odds ratio of 7.7 (95% CI
5.3–11.4) in patients with recurrent reflux symptoms and 43.5 (95% CI 18.3–
103.5) amongst patients with chronic and long-standing symptoms (920years)
[20]. Historically, chronic GORD has thus been the sole symptom used for
initiating entry into BO/OAC endoscopic screening programmes. However,
approximately 40% of patients with OAC do not present with chronic reflux
symptoms despite having severe GORD [21]. This so-called “silent reflux” is
thought to be explained by a reduction in oesophageal sensitivity to acid
refluxate following metaplastic conversion to BO [22]. Nevertheless, using
GORD as a screening criterion has its indisputable merits as modelling on the
adult US population indicates that screening test would be most impactful in
symptomatic GORD patients since they are responsible for 52% of all cancer
cases and necessitate screening only 20% of the population [23]. In this scenar-
io, the term “diagnostic test”may be amore fitting word to use than “screening”
since only symptomatic persons are being tested unless individuals are invited
pro-actively dependent on a search of prescribing databases for example.
The cost benefits of targeted screening have led to the modification of
recommendations in current society guidelines to consider additional risk
factors like family history, central adiposity, Caucasian ethnicity and male sex
[19, 24–26]. There is also concern about the risks of over-diagnosis and over-
treatment since the use of symptoms and risk factors is a blunt tool to predict
BO and is difficult to implement, and it remains the case that the majority of
patients diagnosed will not progress to OAC. Hence, combinatorial risk models
are required taking into account the feasibility of applying an algorithm in
clinical practise.
Risk prediction models
An alternative two-stage screening approach has been sought whereby a subset
of patients identified as having an increased probability of having BO are
screened in a primary care setting with a less expensive and less invasive test
and then referred for endoscopy confirmation. Statistical risk predictionmodels
using widely available and easy to obtain symptoms and risk factors have been
developed to estimate the absolute risk that an individual has BO or would
develop OAC [27]. For example, a BO prediction model based on electronic
health records (EHR) data including gastroesophageal reflux disease, sex, body
mass index and ever-smoker status was shown to identify BO patients with a
modest accuracy reporting an AUC of 0.71 (95% CI 0.64–0.77) [28]. With risk
prediction tools, there is an added potential opportunity for self-assessment
whereby a patient can produce a personalised risk profile for BO using a web-
based application. Despite the accessibility-related benefits and cost-effective-
ness, none of these models is ideal having reported AUCs ranging from 0.61 to
0.75 [27, 29]. Rosenfeld et al. recently developed and validated a machine
learning-based risk prediction model for BO (called MARK-BE) using a com-
prehensive panel of 8 features observed to be significantly associated with
increased risk of BO (age, sex, cigarette smoking, waist circumference, frequency
of stomach pain, duration of heartburn and acidic taste and taking acid
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suppressants) [30•]. TheMARK-BEmodel appears to bemore robust than other
BO risk prediction algorithms published previously due to the large datasets
used in the study and the cross validation performed. The model was trained
internally with a dataset (collected from BEST 2 case-control screening study
(ISRCTN 12730505)—training dataset (n = 776), testing dataset (n = 523)) and
subsequently validated externally in an independent dataset (collected from the
BOOST case-control study (ISRCTN 58235785) n = 398) reporting an area
under the receiver-operator curve (AUC) of 0.81 (95% CI 0.74–0.84, sensitivity
set at 90% and specificity of 58%). Although these results look promising, the
findings have to be validated in a primary care setting and the optimal thresh-
olds of risk at which screening is warranted using this model have to be
determined.
For the current screening paradigm to be successful in OAC prevention, we
need to identify the “at-risk” population with greater precision and/or develop
other safe, economically viable, minimally invasive screening techniques that
can allow effective, systematic screening for BO. For instance, an attractive
strategy of “precision cancer prevention” has been proposed whereby a 5-tier
system is used to stratify individuals into more precise risk groups with each
group being allocated risk-appropriate screening and management options
[23]. For example, individuals belonging to the lowest risk strata would require
minimal intervention and simple cost-effective screening tools whereas high-
risk groups would be eligible for more precise but also more invasive and
expensive techniques (Fig. 1). Such a comprehensive and tailored screening
protocol would not only incorporate a wider population base, including indi-
viduals who are dismissed by current guidelines, but also leverage the use of
Fig. 1.. Three-tier precision cancer prevention strategy.
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confirmatory endoscopy only in situations where it is warranted thus saving
resources.
Screening with the use of imaging techniques
As noted, although white light endoscopy remains the cornerstone of the
current BO screening practise, it is unlikely to be suitable for mass screening
and even routine screening of at-risk individuals because of the direct and
indirect cost burden associated with sedation [31] and side effects [32], albeit
a highly safe and generally well-tolerated procedure. Trans-nasal endoscopy
(TNE) is an alternative endoscopic technique that uses ultra-thin endoscopes
(outer diameter G6mm) performed in the sitting position with the instrument
inserted through the nose for endoscopic imaging of the distal oesophagus.
TNE reduces gagging and vomiting risk thus improving patient tolerability
making it more suited for implementation in primary care [33–35]. It has also
been used in mobile research vans for oesophageal assessment and screening
for BO in the community [36]. In expert hands, TNE is as sensitive and specific
as standardOGD in detecting BO in at-risk population [37]. Result fromameta-
analysis of 34 studies with 6659 patients showed a comparable technical
success rate (94.0% and 97.8%, respectively) from both TNE and OGD with a
significantly higher proportion of patients preferring the former method [38].
TNE is thus recommended in recent guidelines for BO screening due to its
comparable diagnostic accuracy, improved patient tolerability and lower direct
and indirect cost. This technique has however not been widely embraced, and
thismay reflect its limited availability, since it requires investment in specialised
equipment, decontamination facilities and trained operators, as well as attitu-
dinal barriers amongst clinicians and patients. Further modifications have been
carried out on the original TNE to overcome these limitations. The EG Scan TM
II (Intromedic Ltd., Seoul, South Korea) is a second-generation TNE device
comprising a disposable trans-nasal video esophagoscope with a compact
image processing unit. In a tertiary population, with an increased BO preva-
lence, the EG Scan has been shown to be feasible, safe and capable of detecting
BO of any length with a sensitivity value of 0.90 (95% CI, 0.83–0.96) and a
specificity value of 0.91 (95% CI, 0.82–0.96), in comparison to conventional
esophagogastroduodenoscopy [39]. It also had a high acceptability rate
amongst the 89% of participants in the study. Of note, TNE devices have little
to no biopsy sampling capabilities and cannot be used for endoscopic therapy.
Since biopsy-based diagnosis currently holds the most accurate clinical diag-
nostic value for BO and OAC, such tools may thus only be useful in two-step
screening programme where they could be used for preliminary triage testing in
order to enrich the population and then subject individuals with suspected BO
to conventional endoscopy for acquisition of multiple, larger, surveillance
biopsies to detect dysplasia and enable risk stratification and treatment.
Oesophageal capsule endoscopy, an alternative to the TNE technology,
comprises a wireless pill-sized capsule enclosed with a camera, battery and
radio transmitter. Images are transmitted by the radio to a digital receiver worn
on the waist of the patient and subsequently downloaded into a computer
(approximately 8 hrs later) for analysis. Like TNE, OCE does not require
sedation and can be carried out in an office setting. The advantage of OCE over
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conventional TNE is that it is a single-use device obviating the need for equip-
ment reprocessing. The traditional OCE technology has however been reported
to have suboptimal diagnostic accuracy with rapid oesophageal transit times
which could hinder thorough inspection of the oesophagus [40]. Therefore,
newer versions of OCE have been developed so called wireless capsule endos-
copy in efforts to overcome problems of rapid oesophageal transit and to allow
prolonged imaging and inspection of suspected areas. An example of such
innovative modification is the detachable magnetically controlled capsule en-
doscopy [41]. Tethered capsule endomicroscopy is another variant of OCE that
uses optical frequency domain imaging technology [42] to capture 3-dimen-
sional, cross-sectional microscopic images of the entire oesophagus. Subtle
tissue microscopic subsurface information that can otherwise be missed by
endoscopy is thus provided without requiring microscopic assessment of sam-
pled biopsies. Studies on TCE are promising as the method has been shown to
be safe, capable of distinguishing patients with and without BO and feasible in
primary care setting for screening BO [43, 44].
Despite great strides made with the OCE technology, larger prospective
studies in the relevant primary care population are needed to assess cost-
effectiveness and the diagnostic accuracy of these methods for the identification
and surveillance of preneoplastic or neoplastic oesophageal lesions.
Non-endoscopic cell collection devices coupled with
biomarkers—Cytosponge, EsophaCap and EsoCheck
An alternative strategy to the use of imaging for BO screening would be to sample
cells along the oesophagus using minimally invasive non-endoscopic devices and
subsequent analysis of molecular aberrations and/or cytopathologic features asso-
ciated with BO on the cells collected. Non-endoscopic cytological methods have
historically been investigated as screening and early detection tools for oesophageal
squamous cell cancer in high prevalence countries particularly China. Although
these minimally invasive techniques such as brush cytology, mesh and balloon
samplers were safe in the majority of study subjects with minimal adverse effects
reported, none of these historic studies lead to implementation of the methods
established in population-based screening programme owing to poor test sensitiv-
ity of traditional cytology. This led the Fitzgerald lab to develop an alternative
minimally invasive cell collection device that would retrieve a higher number of
cells in an operator independent manner and to augment cytological examination
with biomarkers. Although this approach has not yet been recommended in
current society guidelines, the recent technical advances and randomised trial data
are moving towards clinical implementation.
The main non-endoscopic cell collection devices currently at different stages
of development include the Cytosponge (Covidien products, Medtronic, Minne-
apolis), EsophaCap (Capnostics, Doylestown) and EsoCheck (Lucid Diagnostics,
New York) with each technology having its specific strengths and limitations
(Table 1). These devices were developed with the intent to be used for large-scale
triage testing in the diagnostic or screening setting, and as such, the procedure is
performed by a trained nurse or physician, and a positive result test would
warrant a follow-up confirmatory diagnosis via the standard OGD method.
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Table 1. Key differences in the three non-endoscopic cell collection devices studied for the detection of Barrett’s
oesophagus
Test Cytosponge-TFF3 EsophaCap with 5 gene
methylation panel
EsoCheck with EsoGuard (2
gene methylation panel)
Device type Pan-oesophageal sampling device Pan oesophageal sampling device Targeted distal oesophagus
sampling device
Characteristics Not operator dependent Not operator dependent Operator-dependent balloon
inflation and deflation
Biomarkers TFF3–IHC with potential for AI-assisted reporting [45,
46]
MDMs: VAV3, ZNF682, NDRG4,
FER1L4, and ZNF568 [47]
MDMs: VIM and CCNA1 [48]
Safety record •Detachment rate
•1/2672 (G0.1%) [49]
•1/1654 (G0.1%) [50••]
•Minor bleeding: 1/2672 (G0.1%) [49]
•Sore throat : 63/1654 (4%) [50••]
5/268 (2%) reported AE-1 tether
detachment and 4 other events
[47]
No AE recorded, and data on
safety is limited [48]
Evidence trial
type
•Multicentre cohort study in primary care (BEST1) [51]
•A multicentre case control study—11 UK hospitals
(BEST2) [52]
•RCT (cluster and individual randomised) in 913,000
individuals in primary care (BEST3) [50••]
Multisite case-control
study—three tertiary care
centres and 1 community
hospital in the US [47]
Non-randomised observational
study—1 tertiary care







BEST2 study: 1110 [52] (463 controls, 647 BO),
sensitivity = 79.9%; 87.2% (≥ 3 cm BO), (per
protocol including inadequate sampling), and
specificity = 92.4%
295 (89 controls, 112 BO, 67
indeterminate) [47], sensitivity
= 92%, and specificity = 94%
156 (36 controls, 42 BO) [48],
sensitivity = 90.3%, and
specificity = 91.7%
Overall acceptability score (10-scale grading) High score most acceptable
6 (IQR 5–8), n= 2418
9 (IQR 8–10), n=1654
Low score most acceptable





Primary endpoint: detection Barrett’s increased with rate















Observational, multicentre implementation research
study (ISRCTN91655550)
Case-control study, n= 2500
(ClinicalTrials.gov Identifier:
NCT04214119)
Multicentre single-arm study, n=
1000 (ClinicalTrials.gov
Identifier: NCT04293458)
IHC immunohistochemistry, MDMs methylated DNA markers, AE adverse effect, OGD oesophagogastroduodenoscopy, BO Barrett’s oesophagus,
BEST Barrett’s oesophagus screening trial
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The Cytosponge comprises a 30-mm polyurethane sponge, compressed
within a gelatine capsule about the size of a vitamin pill attached to a string.
Once the patient swallows this capsule and it reaches the gastric cardia, the
tightly packed capsule opens up to form a sponge. Cells lining the entire length
of the oesophagus and oropharynx are collected when the Cytosponge is
retrieved by pulling on the attached string. Similar to the Cytosponge, the
EsophaCap is also a sponge on string device although slightly smaller and softer
than the Cytosponge but likewise comprises a swallowable encapsulated
sponge attached to a tether. The EsoCheck on the other hand is a swallowable
balloon-based oesophageal sampling device comprising of a collapsible encap-
sulated balloon attached to a thin silicone catheter which is connected to a
syringe. When the operator identifies the pressure change of the lower oesoph-
ageal sphincter the balloon is inflated by injecting air via the catheter, the
balloon is gently withdrawn into the distal oesophagus sampling cells from
5–6cm above the GOJ. The device is designed to selectively target the distal
oesophagus for sampling as subsequent deflation of the balloon through the
catheter results in its inversion back into the capsule thus protecting the ac-
quired bio-sample from further dilution or potential contamination by proxi-
mal oesophagus during the capsule retrieval process through the mouth. This
more targeted sampling with EsoCheck increases the signal-to-background-
noise ratio. However, this feature makes the sample acquisition process more
operator dependent. The Cytospongemesh has amore abrasive surface than the
balloon thus allowing deeper samples to be collected. Oesophageal cytology
cells captured by these devices are analysed using biomarkers ascertained for
their sensitivity and specificity for BO and with the potential to add biomarkers
for dysplasia detection.
Although samples collected via the Cytosponge can be assayed for several
biomarkers including methylation [53], multigene next-generation sequencing
panels [54], and microRNAs [55] useful for screening and surveillance, the
current modus operandi for detecting BO from specimens obtained using this
device is immunohistochemical staining of Trefoil Factor Protein 3 (TFF3)
which is an indicator of intestinal metaplasia (the histopathological feature of
BO). The slide-based technique permits the identification of gastric columnar
cells as a quality control metric to ensure that the sampling device reached the
stomach. In addition, other morphological features can be assessed including
atypia indicative of dysplasia and inflammation, as well as application of
additional biomarkers for p53 aberration and an immune-histochemical sur-
rogate for copy number [52, 56]. The other two cell sampling technologies use
BO-related methylated DNA biomarkers (MDMs), which unlike immunohis-
tochemical staining, do not require subjective interpretation by a pathologist
since MDMs can be scalable for automated high throughput testing. Moreover,
a methylation-based circulating biomarker, (Epi proColon, Epigenomics) was
approved by the U.S. Food and Drug Administration for colorectal cancer
screening in 2016 [57].
Evidence for Cytosponge-TFF3
Stepwise clinical trial evidence has been accrued for the Cytosponge-TFF3
procedure to determine safety, acceptability and efficacy. A multicentre case
control study demonstrated a specificity for diagnosing BE of 92.4% (95% CI
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89.5–94.7%) with a sensitivity of 79.9% (95% CI 76.4–83.0%), increasing to
87.2% (95% CI 83.0–90.6%) for patients with ≥3 cm of circumferential BO,
known to confer a higher cancer risk. This was a per protocol analysis that
included cases in whom the device did not reach the stomach. The sensitivity
was 990% when columnar cells were present on the sample, and in the
subsequent BEST3 trial, a repeat Cytsoponge test was recommended in this
situation [58]. The BEST3 randomised controlled screening trial has shown that
the systematic offer of this test to individuals with heartburn symptoms results
in a 10-fold increase in the diagnosis of BO compared to usual care which
entailed endoscopy as deemed necessary by the general practitioner [50••].
Furthermore, a comparative modelling study highlighted the cost-effectiveness
of using Cytosponge to screen symptomatic GORD patients followed by con-
firmatory endoscopy-based diagnosis in Cytosponge positive cases having esti-
mated a 27–29% reduction in screening cost using this approach in comparison
to screening with endoscopy alone [59]. Iqbal et al. conducted an independent
systematic review of 13 relevant studies to assess the efficacy and safety of the
Cytosponge against the endoscopy/biopsy gold standard and reported promis-
ing results [60]. A recent systematic review of 5 large prospective trials evaluat-
ing Cytosponge performance in 2672 procedures showed the device to be safe
and well-tolerated amongst patients with only 2 resolvable serious adverse
events denoted to be directly attributed to the device and most patients (
91.1% ) swallowed the Cytosponge, most on the first attempt (90.1%) [49].
The favourable safety profile and relative ease of the Cytosponge procedure in
comparison to endoscopy makes it a promising screening tool in primary care
setting. An implementation study, called DELTA, is currently underway in the
UK to establish the practical steps for introduction into routine clinical care and
to further evaluate cost-effectiveness and patient preferences to maximise
uptake.
EsophaCap biomarker
The EsophaCap was first tested in a pilot trial that reported the feasibility of
using a 2-MDM model (vav guanine nucleotide exchange factor 3-VAV3 and
zinc finger protein 682-ZNF682) with the EsophaCap to diagnose BO achieving
100% sensitivity and specificity in a highly enriched population comprising 20
BO patients 10 of whom had dysplasia and 20 controls [61]. No major
complications were observed and only 32% of patients who swallowed the
capsule had minimal abrasion without bleeding. The same group went on to
conduct a multisite case-control study comprising 295 patients across 2 geo-
graphically distinct tertiary care centres and 1 community hospital in the United
States (US) to assess the accuracy of the pre-established MDMs in a separate
cohort [47]. They used a recently validated commercial grade assay (target
enrichment long-probe quantitative amplified signal (TELQAS)) to achieve this
[62] . In this study, 91% of consented participants swallowed the capsule of
which 112were categorised as BO cases, 89 as controls and 67 as indeterminate.
The indeterminate group was studied separately following the primary analysis
on cases and controls. VAV3 and ZNF682—the two MDMs discovered in the
pilot trial—were included along with 3 additional markers NDRG4, FER1L4,
and ZNF568 yielding a sensitivity and specificity of 92% (95%CI 85–96%) and
94% (95% CI 87–98%), respectively. Five patients (7%) encountered technical
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issues including device intolerance and tether detachment during the adminis-
tration of the device and 1 inadequate DNA sample was reported. The proce-
dure was nevertheless successfully undertaken by non-physicians in most study
subjects, and the device was well-tolerated (median [interquartile range] toler-
ability 2 [0, 4] on 10-scale grading) with 248 study participants (94%) prefer-
ring the EsophaCap over OGD. Although the model accuracy was not influ-
enced by age, sex or smoking history, as expected BO length altered the perfor-
mance with four short segment, non-dysplastic BE cases missed by the model.
Furthermore, no statistically significant difference was reported between the
sensitivity of the 5-marker panel for non-dysplastic BO and dysplastic BP. A
case-control study with 2500 participants in the US is ongoing to identify
optimal DNA methylation biomarkers for the early detection of BO, oesopha-
geal carcinoma and gastric cancer via EsophaCap-derived specimens
(ClinicalTrials.gov Identifier: NCT04214119).
EsoCheck biomarker
The EsoCheck device has been investigated with a two-marker MDM panel
vimentin (VIM) and cyclin-A1 (CCNA1). A pilot trial conducted across patients
(36 controls, 42 BO cases (31 non-dysplastic, 6 LGD, 4 HGD and 1 indefinite
for dysplasia) and 8 with EAC or junctional cancers) reported a sensitivity and
specificity of 90.3% and 91.7% for BO detection [48]. Although the device was
generally well-tolerated, 18% of study participants could not swallow the device
and the investigators reported poor DNA yield in an additional 9% who were
excluded from the analysis. Modifications in the design of the original
EsoCheck device was shown to improve the device’s failure to swallow rate
and increased DNA yield for diagnosing BO/OAC [63]. In comparison with
OGD, the efficacy of the newer generation EsoCheck device in combination
with 2-marker MDM panel assay for the diagnosis of BO in at risk screening
population is currently being tested in a multicentre single-arm study with a
sample size of 1000 subjects in the US (ClinicalTrials.gov Identifier:
NCT04293458).
Liquid biopsy
Alternative non-invasive approaches for BO detection include the use of liquid
biopsy whereby BO or early cancer-related biomarkers are assessed via an
individual’s peripheral blood or breath samples. Blood or breath sampling is
highly feasible and minimally invasive and is therefore more likely to improve
acceptability and tolerability of BO screening. However, the most pressing
challenge with these approaches is the ability to achieve accurate sensitivity
and specificity whilst minimising false positives as well as the need to depend
on further tests to confirm BO/early cancer diagnosis.
Circulatory miRNAs and DNA analysis
MicroRNAs (miRNAs), small single-chain non-coding ribonucleic acids (RNAs)
(18–25 nucleotides long) responsible for the regulation of physiological pro-
cesses, have been investigated as biomarkers for BO/early OAC detection as
both tissue-based and blood-based biomarkers [64]. The first circulatory
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miRNA expression profiling study in BO and OAC patients identified a panel 4
miRNA targets (miRNA-95-3p, miRNA-136-5p, miRNA-194-5p and miRNA-
451a). Further validation in the same study yielded AUC of 0.832 (95% CI
0.698 – 0.967) with 78.4% (95%CI 61.8–90.2) sensitivity and 85.7% (95%CI
57.2–98.2) specificity reported [65]. miR-143, miR-194 and miR-215 are also
upregulated in the serum of BO patients in comparison to patients with non-
metaplastic esophagitis [66]. Recently, miR-130a [67] as well as miR-320e and
miR-199a-3p [68] have also been identified in BO. Despite the increasing
number of BO-related circulatory miRNAs discovered in current literature, the
lack of validatory studies on these targets have limited their clinical use for BO
screening. Moreover, a recent study investigating differential miRNA signatures
for BO and OAC reported a discordance between serum and tissue miRNA
profiles [69]. In contrast to tissue-borne miRNAs which demonstrated an
accuracy of 80% in classifying samples into normal, BO/GERD or LGD/OAC,
the study failed to identify serum miRNA signature of disease state. This may
limit the use of circulating miRNAs for early disease screening.
Circulating tumour DNA (CtDNA), often coupled with methylation and
proteins from the plasma, is another minimally invasive method for detect-
ing, studying and monitoring cancer. Although great progress is being made
using the approach for a pan-cancer early detection test [70], it is unclear if
sufficient sensitivity can be reached for early OAC screening considering that
premalignant BO and dysplastic lesions are usually encapsulated within an
intact basement membrane. Hence, it may not be biologically feasible to
detect pre-invasive lesions using these technologies but it is too soon to draw
conclusions.
Volatile organic compounds in exhaled breath samples
Evaluation of volatile organic compounds (VOCs) in exhaled breath samples is
another non-invasive approach shown to hold promise for diagnosis of various
cancer types [71]. A systematic review and pooled analysis of 63 published VOC
breath tests for cancer reported an AUC of 0.94, sensitivity of 79% (95%CI 77–
81%) and specificity of 89% (95% CI 88–90 %) [72]. However, 41 of the
studies analysed in the aforementioned review did not explore the role of cancer
stage on the performance of the breath test. The other 22 studies on the other
hand reported inconsistent findings.
The two main techniques currently adopted for breath sample analysis in
BO/OAC patients include chemical analytical techniques, like gas
chromatography-mass spectrometry [73, 74] and the electronic nose device
(e-nose) (Aeonose, The eNose Company, Zutphen, Netherlands), which uses
a 3 metal-oxide sensor array [75, 76]. Chemical analytical techniques are
however generally more expensive and labour intensive whereas the e-nose is
a more portable device with the potential for obtaining real-time breath anal-
ysis. A recent proof-of-concept study involving 402 individuals (BO patients =
129, GORD patients = 242 and control group = 132) reported the patient
acceptability rate of the e-nose device to be 91.4% and demonstrated the
possibility of accurately detecting BO in patients with and without GORDusing
VOC breath analysis with the e-nose device [76]. The VOC-based model devel-
oped and cross-validated in this study generated an AUC of 0.91 (95%CI 0.87–
0.94) with 91% (95% CI 84–95%) sensitivity and 74% (95% CI 69–79%)
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specificity reported for BO prediction. More validation studies in larger inde-
pendent cohort are warranted to confirm these promising results.
Conclusion
Current screening guidelines for BO recommend against mass screening since
the standard method for BO diagnosis and monitoring, OGD is invasive and
expensive thus making it an inappropriate screening tool for a relatively un-
common cancer like OAC. This is even a more pressing issue considering that
the ongoing pandemic has resulted in limited access to diagnostic services.
Most guidelines advocate for targeted screening approach whereby individ-
uals who are most at risk of developing BO are subjected to endoscopic
screening and then surveillance if warranted. However, this approach is not
impacting on the highmortality fromOAC. In order to improve this situation, a
new clinical pathway designed to systematically identify the at-risk population
for BO has to be set in place. Furthermore, cost-effective, less invasive screening
tools are needed to improve accessibility to screening opportunities. Indeed,
great strides are being made in these two areas. Cost-effective, easily accessible
risk prediction algorithms have for instance been tested as a modality for
identifying and enriching the population for BO screening. Although the ma-
jority of algorithms developed thus far have reported fair AUC’s, they may still
be capable of serving enrichment purposes when used in adjunct with other
more accurate screening tools. More prospective evaluation of such algorithms
is required.
As regards endoscopy alternatives, newer generation of imaging techniques
like TCE and OCE have undergone a series of modifications to improve porta-
bility and reduce operator dependence increasing their practicality for mass
screening. Considering that biopsy sampling is limited with these technologies,
in-depth assessment of the diagnostic accuracy of these tests in primary care
setting is warranted. Non-endoscopic cell collection device coupled with bio-
marker analysis is another promising area with randomised controlled trial
level evidence to support the utility of Cytoposnge-TFF3 to identify BO.
Combining all the different areas of screening discussed thus far, a three-tier
precision cancer prevention-based screening programme whereby (i) easily
accessible BO risk assessment algorithms are used for population-wide first-
stage screening, (ii) more accurate, cost-effective and minimally invasive tools
like TNE/OCE, non-endoscopic cell collection devices or liquid biopsies are
used to further triage test the at-risk population in primary care setting, and (iii)
suspected cases of BO or early cancer are subsequently followed up using
standard endoscopy, could improve the effectiveness of the screening process.
By following such a regimen, screening would be made accessible to a larger
pool of individuals in an affordable manner thus reducing the number of BO
cases that are missed by current practises.
With the ongoing debate on the benefit of BO surveillance, there needs to be
studies evaluating the impact of BO screening using these new technologies on
overall diseasemortality. Furthermore, the low progression rate of BO as well as
associated psychological stress amongst many other negative consequences of
BO diagnosis reinforce the need for efforts to continuously be made on devel-
oping robust biomarker panel that can risk stratify BO patients. Only when this
Endoscopy (P Siersema, Section Editor)332
Screening for Barrett’s Oesophagus: Are We Ready for it Yusuf and Fitzgerald
is reached would we be able to unlock the full potential of BO screening for
improved clinical outcomes of OAC.
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